Mechanism of action of a new antitumor agent, carbetimer

Bach Ardalan, G. E. Paget

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Carbetimer, an intermediate molecular-weight-derivatized copolymer of maleic anhydride and ethylene, has been shown to possess significant antineoplastic activity in the stem cell assay. We have examined the antitumor activity of carbetimer in vivo and in vitro against HM5-Carb/S and M21, both primary human melanoma cell lines sensitive and resistant to carbetimer, respectively. The mechanism of action of carbetimer in HM5-Carb/S has been determined. Mice bearing palpable sensitive tumors were treated with 10% lethal doses of carbetimer (1500 mg/kg i.p.). The tumor nucleotide profile was determined 4 hours later. Uridine and cytidine nucleoside triphosphates were reduced by 36.6 and 58.2%, respectively. In a similar experiment using carbetimer-resistant tumor, there was no change in the tumor pool sizes of uridine and cytidine nucleoside triphosphate pools in carbetimer- or saline-treated animals. Following 24-h exposure of the cells to 1000 μM concentration of carbetimer, the carbetimer-sensitive cells were pulsed with [14C]uridine, cytidine, or thymidine for 30 min. Pyrimidine nucleotides, in particular triphosphates, were reduced significantly as compared to the saline-treated control. Similar treatment of carbetimer-resistant cells resulted in no change in the pool sizes of the nucleotides. [14C]Bicarbonate flux studies demonstrated that [14C]CO2 conversion into UMP and CMP was increased 200 and 140% of control in the carbetimer-sensitive cells treated with 1000 μM carbetimer; however, a similar treatment of the resistant cells showed no change in the pool sizes of the nucleotide. Examination of pyrimidine salvage enzymes demonstrated that, in the sensitive cells, carbetimer treatment reduced the specific activity of uridine, cytidine, and thymidine kinase by 46, 37, and 60%. In a similar study using resistant cells, the specific activities were reduced 7 and 0%, respectively. In the restitution studies coincubation of carbetimer-sensitive cells with carbetimer and uridine resulted in essentially the reversal of carbetimer cytotoxicity. Thus, carbetimer inhibits the growth of the sensitive cells by inhibiting the uptake and metabolism of preformed nucleosides both in vivo and in vitro.

Original languageEnglish
Pages (from-to)5473-5476
Number of pages4
JournalCancer Research
Volume46
Issue number11
StatePublished - Dec 1 1986
Externally publishedYes

Fingerprint

Antineoplastic Agents
Uridine
Nucleosides
Cytidine Triphosphate
carboxyimamidate
Nucleotides
Neoplasms
Uridine Kinase
Colony-Forming Units Assay
Pyrimidine Nucleotides
Uridine Monophosphate
Cytidine Monophosphate
Cytidine
Thymidine Kinase
Bicarbonates
Thymidine
Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mechanism of action of a new antitumor agent, carbetimer. / Ardalan, Bach; Paget, G. E.

In: Cancer Research, Vol. 46, No. 11, 01.12.1986, p. 5473-5476.

Research output: Contribution to journalArticle

Ardalan, B & Paget, GE 1986, 'Mechanism of action of a new antitumor agent, carbetimer', Cancer Research, vol. 46, no. 11, pp. 5473-5476.
Ardalan, Bach ; Paget, G. E. / Mechanism of action of a new antitumor agent, carbetimer. In: Cancer Research. 1986 ; Vol. 46, No. 11. pp. 5473-5476.
@article{f8553aa8c9ff4a40bde17d3ddf7e080a,
title = "Mechanism of action of a new antitumor agent, carbetimer",
abstract = "Carbetimer, an intermediate molecular-weight-derivatized copolymer of maleic anhydride and ethylene, has been shown to possess significant antineoplastic activity in the stem cell assay. We have examined the antitumor activity of carbetimer in vivo and in vitro against HM5-Carb/S and M21, both primary human melanoma cell lines sensitive and resistant to carbetimer, respectively. The mechanism of action of carbetimer in HM5-Carb/S has been determined. Mice bearing palpable sensitive tumors were treated with 10{\%} lethal doses of carbetimer (1500 mg/kg i.p.). The tumor nucleotide profile was determined 4 hours later. Uridine and cytidine nucleoside triphosphates were reduced by 36.6 and 58.2{\%}, respectively. In a similar experiment using carbetimer-resistant tumor, there was no change in the tumor pool sizes of uridine and cytidine nucleoside triphosphate pools in carbetimer- or saline-treated animals. Following 24-h exposure of the cells to 1000 μM concentration of carbetimer, the carbetimer-sensitive cells were pulsed with [14C]uridine, cytidine, or thymidine for 30 min. Pyrimidine nucleotides, in particular triphosphates, were reduced significantly as compared to the saline-treated control. Similar treatment of carbetimer-resistant cells resulted in no change in the pool sizes of the nucleotides. [14C]Bicarbonate flux studies demonstrated that [14C]CO2 conversion into UMP and CMP was increased 200 and 140{\%} of control in the carbetimer-sensitive cells treated with 1000 μM carbetimer; however, a similar treatment of the resistant cells showed no change in the pool sizes of the nucleotide. Examination of pyrimidine salvage enzymes demonstrated that, in the sensitive cells, carbetimer treatment reduced the specific activity of uridine, cytidine, and thymidine kinase by 46, 37, and 60{\%}. In a similar study using resistant cells, the specific activities were reduced 7 and 0{\%}, respectively. In the restitution studies coincubation of carbetimer-sensitive cells with carbetimer and uridine resulted in essentially the reversal of carbetimer cytotoxicity. Thus, carbetimer inhibits the growth of the sensitive cells by inhibiting the uptake and metabolism of preformed nucleosides both in vivo and in vitro.",
author = "Bach Ardalan and Paget, {G. E.}",
year = "1986",
month = "12",
day = "1",
language = "English",
volume = "46",
pages = "5473--5476",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Mechanism of action of a new antitumor agent, carbetimer

AU - Ardalan, Bach

AU - Paget, G. E.

PY - 1986/12/1

Y1 - 1986/12/1

N2 - Carbetimer, an intermediate molecular-weight-derivatized copolymer of maleic anhydride and ethylene, has been shown to possess significant antineoplastic activity in the stem cell assay. We have examined the antitumor activity of carbetimer in vivo and in vitro against HM5-Carb/S and M21, both primary human melanoma cell lines sensitive and resistant to carbetimer, respectively. The mechanism of action of carbetimer in HM5-Carb/S has been determined. Mice bearing palpable sensitive tumors were treated with 10% lethal doses of carbetimer (1500 mg/kg i.p.). The tumor nucleotide profile was determined 4 hours later. Uridine and cytidine nucleoside triphosphates were reduced by 36.6 and 58.2%, respectively. In a similar experiment using carbetimer-resistant tumor, there was no change in the tumor pool sizes of uridine and cytidine nucleoside triphosphate pools in carbetimer- or saline-treated animals. Following 24-h exposure of the cells to 1000 μM concentration of carbetimer, the carbetimer-sensitive cells were pulsed with [14C]uridine, cytidine, or thymidine for 30 min. Pyrimidine nucleotides, in particular triphosphates, were reduced significantly as compared to the saline-treated control. Similar treatment of carbetimer-resistant cells resulted in no change in the pool sizes of the nucleotides. [14C]Bicarbonate flux studies demonstrated that [14C]CO2 conversion into UMP and CMP was increased 200 and 140% of control in the carbetimer-sensitive cells treated with 1000 μM carbetimer; however, a similar treatment of the resistant cells showed no change in the pool sizes of the nucleotide. Examination of pyrimidine salvage enzymes demonstrated that, in the sensitive cells, carbetimer treatment reduced the specific activity of uridine, cytidine, and thymidine kinase by 46, 37, and 60%. In a similar study using resistant cells, the specific activities were reduced 7 and 0%, respectively. In the restitution studies coincubation of carbetimer-sensitive cells with carbetimer and uridine resulted in essentially the reversal of carbetimer cytotoxicity. Thus, carbetimer inhibits the growth of the sensitive cells by inhibiting the uptake and metabolism of preformed nucleosides both in vivo and in vitro.

AB - Carbetimer, an intermediate molecular-weight-derivatized copolymer of maleic anhydride and ethylene, has been shown to possess significant antineoplastic activity in the stem cell assay. We have examined the antitumor activity of carbetimer in vivo and in vitro against HM5-Carb/S and M21, both primary human melanoma cell lines sensitive and resistant to carbetimer, respectively. The mechanism of action of carbetimer in HM5-Carb/S has been determined. Mice bearing palpable sensitive tumors were treated with 10% lethal doses of carbetimer (1500 mg/kg i.p.). The tumor nucleotide profile was determined 4 hours later. Uridine and cytidine nucleoside triphosphates were reduced by 36.6 and 58.2%, respectively. In a similar experiment using carbetimer-resistant tumor, there was no change in the tumor pool sizes of uridine and cytidine nucleoside triphosphate pools in carbetimer- or saline-treated animals. Following 24-h exposure of the cells to 1000 μM concentration of carbetimer, the carbetimer-sensitive cells were pulsed with [14C]uridine, cytidine, or thymidine for 30 min. Pyrimidine nucleotides, in particular triphosphates, were reduced significantly as compared to the saline-treated control. Similar treatment of carbetimer-resistant cells resulted in no change in the pool sizes of the nucleotides. [14C]Bicarbonate flux studies demonstrated that [14C]CO2 conversion into UMP and CMP was increased 200 and 140% of control in the carbetimer-sensitive cells treated with 1000 μM carbetimer; however, a similar treatment of the resistant cells showed no change in the pool sizes of the nucleotide. Examination of pyrimidine salvage enzymes demonstrated that, in the sensitive cells, carbetimer treatment reduced the specific activity of uridine, cytidine, and thymidine kinase by 46, 37, and 60%. In a similar study using resistant cells, the specific activities were reduced 7 and 0%, respectively. In the restitution studies coincubation of carbetimer-sensitive cells with carbetimer and uridine resulted in essentially the reversal of carbetimer cytotoxicity. Thus, carbetimer inhibits the growth of the sensitive cells by inhibiting the uptake and metabolism of preformed nucleosides both in vivo and in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0022979401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022979401&partnerID=8YFLogxK

M3 - Article

C2 - 3756894

AN - SCOPUS:0022979401

VL - 46

SP - 5473

EP - 5476

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -